

Daniel J Renouf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6031233/publications.pdf>

Version: 2024-02-01

42
papers

1,635
citations

471061

17
h-index

315357

38
g-index

44
all docs

44
docs citations

44
times ranked

3371
citing authors

#	ARTICLE	IF	CITATIONS
1	Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care. <i>Journal of Community Genetics</i> , 2022, 13, 523-538.	0.5	4
2	The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space. <i>Journal of Molecular Diagnostics</i> , 2022, , .	1.2	0
3	Whole-genome and transcriptome analysis of advanced adrenocortical cancer highlights multiple alterations affecting epigenome and DNA repair pathways.. <i>Cold Spring Harbor Molecular Case Studies</i> , 2022, 8, .	0.7	2
4	Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 522-531.	3.2	14
5	Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 202-212.	3.2	50
6	Matching methods in precision oncology: An introduction and illustrative example. <i>Molecular Genetics & Genomic Medicine</i> , 2021, 9, e1554.	0.6	13
7	Clinical and cost outcomes following genomicsâ€informed treatment for advanced cancers. <i>Cancer Medicine</i> , 2021, 10, 5131-5140.	1.3	8
8	Real-World Outcomes of Oxaliplatin-Based Chemotherapy on R0 Resected Colonic Liver Metastasis. <i>Clinical Colorectal Cancer</i> , 2021, 20, e201-e209.	1.0	0
9	Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms. <i>Cell Reports</i> , 2021, 37, 109817.	2.9	14
10	Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer. <i>Cell Reports Medicine</i> , 2020, 1, 100131.	3.3	52
11	Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-5.	0.8	6
12	Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencing. <i>Genetics in Medicine</i> , 2020, 22, 1892-1897.	1.1	42
13	Integration of Whole-Genome Sequencing With Circulating Tumor DNA Analysis Captures Clonal Evolution and Tumor Heterogeneity in Non-V600 BRAF Mutant Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 132-136.e3.	1.0	1
14	Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a004713.	0.5	5
15	Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis. <i>Investigational New Drugs</i> , 2020, 38, 1601-1604.	1.2	0
16	Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. <i>Nature Cancer</i> , 2020, 1, 452-468.	5.7	103
17	Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma. <i>JAMA Oncology</i> , 2019, 5, 1431.	3.4	417
18	Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. <i>Gastroenterology</i> , 2019, 157, 823-837.	0.6	153

#	ARTICLE	IF	CITATIONS
19	Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003814.	0.5	17
20	Application of a Neural Network Whole Transcriptome-Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers. <i>JAMA Network Open</i> , 2019, 2, e192597.	2.8	67
21	Base excision repair deficiency signatures implicate germline and somatic <i>MUTYH</i> aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003681.	0.5	33
22	Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 196-201.	0.6	12
23	Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a002659.	0.5	3
24	Molecular characterization of <i>ERBB2</i> -amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002535.	0.5	16
25	Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002626.	0.5	18
26	Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma. <i>Npj Precision Oncology</i> , 2018, 2, 8.	2.3	15
27	Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002329.	0.5	30
28	Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 552-554.	0.6	19
29	Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival. <i>Cancer Medicine</i> , 2017, 6, 361-373.	1.3	11
30	Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7521-7530.	3.2	144
31	Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, 179-185.	1.0	38
32	Effect of Adjuvant Chemotherapy on Stage II Rectal Cancer Outcomes After Preoperative Short-Course Radiotherapy. <i>Clinical Colorectal Cancer</i> , 2016, 15, 352-359.e1.	1.0	12
33	Impact of Weight Changes After the Diagnosis of Stage III Colon Cancer on Survival Outcomes. <i>Clinical Colorectal Cancer</i> , 2016, 15, 16-23.	1.0	20
34	Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups. <i>Journal of Clinical Pathology</i> , 2016, 69, 431-439.	1.0	19
35	Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. <i>Cancer Medicine</i> , 2015, 4, 1171-1177.	1.3	94
36	Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. <i>Journal of Physical Education and Sports Management</i> , 2015, 1, a000570.	0.5	92

#	ARTICLE	IF	CITATIONS
37	Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 262-268.e1.	1.0	17
38	Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome. <i>Carcinogenesis</i> , 2015, 36, 956-962.	1.3	7
39	Effect of Delay in Adjuvant Oxaliplatin-Based Chemotherapy for Stage III Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2015, 14, 25-30.	1.0	14
40	Association of <i>MDM2 T309G</i> and <i>p53 A72P</i> polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1482-1488.	1.4	12
41	A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1339-1344.	1.1	9
42	BCL-2 Expression is Prognostic for Improved Survival in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 486-491.	0.5	30